#United States #chitosan #Minnesota #USP Inhalant #iterro Life Sciences

Innovating Medical Applications with trū Chitosan

Trū® Chitosan, a prominent name under iterro Life Sciences, has made headlines by unveiling a pioneering product: the trū Chitosan USP Inhalant. This new inhalant product stands as the first commercial chitosan specifically designed for inhaled drug delivery, adhering to stringent United States Pharmacopeia (USP) standards.

A Breakthrough in Purity and Production

After an extensive three years of research and five years of scaled production efforts, trū Chitosan is setting a new benchmark in the realm of inhaled applications. Brian Knochenmus, the CEO of iterro, described the launch of the USP Inhalant as not just a product release but a monumental achievement in chitosan medical applications. The purity of this inhalant product is seen as a culmination of decades of dedicated research focused on harnessing the medical benefits of chitosan, with an unmatched consistency for inhalation treatments.

According to Dick Pace, PhD and Founder of Parimer Scientific, a key partner in this venture, the evolution of the production process has significantly minimized metal impurities in the inhalant. The transitional journey from raw materials—precisely sourced from shrimp shells—to the final product showcases the collaborative efforts of iterro and Parimer, ensuring that the chitosan not only meets but exceeds USP standards, including the rigorous USP 232 limits for impurities in inhaled substances.

Expanding Medical Applications

The trū Chitosan USP Inhalant is designed to complement existing offerings in the trū Chitosan portfolio, contributing to a variety of medical applications. As stated by Michael Ziebell, COO, trū Chitosan has already gained traction in therapeutic areas such as cancer treatments, surgical aids, and wound care solutions. The USP Inhalant has potential implications for targeting diseases related to the lung, such as those caused by mycobacteria, showcasing a future of innovative medical uses.

In reflecting on the advancements offered by the trū Chitosan USP Inhalant, Dr. Samuel Hudson, a specialist in chitosan research, highlighted the clarity and purity of the product. He praised its molecular consistency, marking it a significant milestone in medical-grade chitosan innovation. The inhalant not only positions trū Chitosan as a leader in the industry but also assures medical professionals of a reliable, traceable product engineered for advanced applications.

Future Prospects and Distribution

Trū Chitosan's plans extend beyond the introduction of the USP Inhalant. With capacity expansion routes mapped out in Madison, South Dakota, including collaboration opportunities through prominent partners like Hawkins Pharmaceuticals for distribution in the U.S., the brand is poised for a broader market presence. Queries related to product integration into research pipelines can be directed to Chris Meyer for national inquiries or Michael Ziebell for international questions—a testament to the company's commitment to facilitating access to their innovations.

As the medical community continues to seek reliable, high-purity materials for various applications, trū Chitosan's groundbreaking inhalant product may just redefine standards and open new avenues for inhalable therapies, further establishing the brand's footprint in the global healthcare landscape.